Health

Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

Vincent JiangVincent Jiangthree-minute read
Share
OpenEvidence's dark home screen with a prompt box reading "Ask a medical question" beside a Clinical Decision Support button and a HIPAA Compliant mark
1 / 6Slide 1 of 6
OpenEvidence's home screen. The free, advertising-funded clinical AI is the engine behind Apple's 200,000-person health study app; Apple built the research app, OpenEvidence supplies the answers.

Two hundred thousand people, and no contract

On Sunday, November 15, 2026, at the HLTH conference in Las Vegas, Apple−0.69% — Apple, down 0.69 percent today and OpenEvidence~$6B — OpenEvidence, private, latest valuation ~$6B launched the Apple Health AI Usage Study: a separate iPhone app where up to 200,000 US adults aged 21 and over ask everyday health questions of an AI built on OpenEvidence, then grade the answers on accuracy, detail and relevance 12. OpenEvidence supplies the clinical engine, grounding responses in the New England Journal of Medicine, JAMA and Nature; Apple built the research experience 14.

Apple says nothing learned will train AI models, and OpenEvidence deletes queries and responses within 24 hours 4. What has not been disclosed is anything commercial: no fee, no investment, no agreement between the two companies 3.

OpenEvidence trades its engine for distribution

The silence is the news. OpenEvidence raised $250 million at a $15 billion valuation in late September, confirmed by CEO Daniel Nadler 5. The model is free physician access funded by advertising; Sacra estimated a $300 million annualized revenue run rate as of end-July 2026, an estimate, not audited accounts 3.

A JAMA study published October 15, 2026, counted 952,008 verified US clinician users and 271 million questions from January 2024 to June 2026, with monthly active users climbing from 355 to 703,265 3.

OpenEvidence already reaches three times the people Apple hopes to enroll

The study is a rounding error next to the audience OpenEvidence already has

0200,000400,000600,000800,000OpenEvidence clinician MAU, Jun 2026703,265Physicians among its verified users556,200Apple study target participants200,000
Data
Value
OpenEvidence clinician MAU, Jun 2026703,265
Physicians among its verified users556,200
Apple study target participants200,000
People, not dollars. The first bar is monthly active US clinicians in June 2026; the second is the physicians inside the 952,008 verified clinician users counted from January 2024 to June 2026 (JAMA study of October 15, 2026, as reported by Economie Matin); the third is Apple's stated enrollment ceiling for the study app, not a count of users. Sources: Economie Matin (3), Apple Newsroom (1).3,1

Apple's endorsement puts a physician-focused tool in front of consumers, and Apple keeps the user relationship and the data. OpenEvidence, by the public record, is trading its clinical engine for distribution. Nadler's own framing at the launch: "Apple is the most trusted and loved brand and product among consumers... you have to bring these two things together" 2.

The trust question cuts both ways

OpenEvidence's valuation rests on doctors' trust; consumer exposure either multiplies the audience or risks medicalizing a professional brand. A March 2026 KFF survey found 32% of US adults had asked an AI chatbot about their health in the prior year, and 77% worried about medical data privacy 3. The stakes of a wrong answer on the phone in someone's pocket are different from those at the point of care.

February 24 is the scoreboard

The listed scoreboard is Wolters Kluwer0.00% — Wolters Kluwer, unchanged today, owner of UpToDate, the paid clinical reference OpenEvidence undercuts. Health grew 5% organically in the nine months to September, with "continued good renewals" for UpToDate Enterprise 7.

Two days before Apple's launch, Wolters Kluwer agreed to buy AgileMD for up to $100 million to push UpToDate Expert AI, now in over 2,700 US hospitals, into EHR workflows 6. Its full-year results on February 24, 2027, will show whether free AI citation engines are denting paid renewals 4. Whether Apple ever ships a health chatbot in the Health app or Siri is undisclosed; the study results will be the tell 4.

Learn more in our earlier reporting on the ACP licensing deal with OpenEvidence and in the sources below.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading AAPL

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Health

    ACP licenses its guidelines to OpenEvidence for an undisclosed price

    The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

    Health

    FDA orders NAION vision-loss warning on every GLP-1 label; Novo Nordisk up 2.65%, Eli Lilly up 4.28%

    The FDA's class-wide vision-loss warning on the world's biggest drug franchise rests on ten probable cases against five among placebo patients; Novo Nordisk and Eli Lilly rose on the news, and hundreds of blindness suits now hold a federal exhibit.

    Health

    Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity

    A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference.

    Subscribe to TheInference for free